Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has entered a key phase in its development, progressing its lead drug candidate, PTX-100, into a Phase 2 trial for T-Cell Lymphomas (TCL). With the drug targeting an urgent need in oncology, analysts from Pitt Street Research have updated their valuation for the company, raising their price target on the back of PTX-100's progress and expanding market potential.
The updated analysis shows an optimistic outlook for Prescient, driven by positive clinical data and the company’s strategic shift towards more advanced trials.
"PTX-100 has shown strong potential in Phase 1, not just trouncing existing standards of care, but working in patients where previous treatments have failed," analysts Stuart Roberts and Nick Sundich noted.
Updated valuation based on Phase 2 progression
Pitt Street analysts now place the base case valuation for Prescient at A$0.146 per share ($118 million) and the bull case at $0.203 per share ($163.2 million). This marks an increase from the previous range of $0.116–0.163 per share ($93.5 million–$131.6 million).
The updated valuation comes as Prescient's PTX-100 enters its critical Phase 2 trial. The analysts reduced the discount rate on future cash flows, reflecting the increasing confidence in PTX-100's success following its Phase 1 results and the progression into Phase 2.
“We have increased the probability factor from 33% to 40% and the passage of time (over 18 months since our first initiation report in November 2023) has meant the discount on future cash flows has decreased,” they wrote.
Market potential for PTX-100 in TCL
T-Cell Lymphoma (TCL), particularly the relapsed and refractory form, is one of the deadliest cancers with limited treatment options. With overall survival rates under a year for many patients, PTX-100 has emerged as a potential breakthrough, Pitt Street said.
"Even though the US market for all TCLs is only 5,000-6,000 patients, the market opportunity could be substantial given the high price PTX-100 could sell for," the analysts explained.
The Pitt Street Research team estimates a US$2.6 billion sales opportunity for PTX-100, with potential for over US$500 million in royalties, assuming the drug achieves approval and is priced similarly to existing treatments like Folotyn, which costs US$450,000 per patient.
Catalysts beyond PTX-100
In addition to the ongoing Phase 2 trial of PTX-100, analysts see several potential value catalysts for Prescient. These include the development of its CAR-T platforms, CellPryme and OmniCAR, both of which aim to improve the efficacy of cancer treatments and overcome current challenges with CAR-T therapies.
But Roberts and Sundich emphasised that the main upside potential lies in the investigation of PTX-100’s ability against other cancers that could be fought with RAS therapies — potentially over 20% of all cancers.
If successful, these platforms could further enhance Prescient’s market positioning in the oncology space, the analysts said.
Risks and opportunities
While the updated valuation for Prescient reflects optimism, Pitt Street’s analysts cautioned that there are risks inherent in the biotech sector, particularly with pre-revenue companies. Key risks include potential delays in clinical trials, regulatory challenges, and technical hurdles related to the new technologies under development.
Despite these risks, the potential for regulatory approval and market success, particularly if PTX-100 proves superior to existing treatments in the Phase 2 trial, positions Prescient well for future growth. The analysts also point to the broader opportunity in the oncology market, where there remains a critical need for more effective therapies for diseases like T-Cell Lymphoma.
Looking ahead
Prescient Therapeutics is continuing to make significant strides with PTX-100 and its other drug development assets, drawing increasing investor attention. Success in the ongoing Phase 2 trial would be a major catalyst for the company, potentially leading to regulatory approval and opening up a lucrative market for PTX-100, Pitt Street Research concluded.
“There is precedent for drugs treating conditions for which there are none on the market to be bought out for substantial valuation,” the analysts said.
“Amgen paid US$27.8 billion to acquire Horizon Therapeutics in 2023 for Tepezza, the only approved treatment for thyroid eye disease. This figure should not be taken literally as what PTX could be bought out for, but it should give a hint that big pharma could pay up in a serious way.”